🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,196 results for “GE” Clear

  1. Solifenacin succinate

    Astellas Pharma Europe B. V.

    Neurogenic Detrusor Overactivity

    phase 3 small molecule completed

    1 trial

  2. Solriamfetol 150 mg

    Axsome Therapeutics

    Binge-Eating Disorder

    phase 3 small molecule active

    1 trial

  3. Solriamfetol 75mg, 150 mg, or 300 mg

    Axsome Therapeutics

    Binge-Eating Disorder

    phase 3 small molecule active

    1 trial

  4. Solution de chlorure de sodium à 0,9%, Allogeneic umbilical cord derived MSC (thawed and washed)

    Pari Pharma GmbH

    Adult Patients kidney transplant recipients who have developed chronic humoral rejection, diagnosed through a kidney biopsy (Banff 2017 Classification), resistant to conventional treatment (3 injections at one-month intervals of 2g/kg of IVIG)

    phase 3 small molecule active

    1 trial

  5. Solution for Injection, subcutaneous Use, IMCIVREE 10 mg/ml solution for injection

    Lacuna Pharma Pty Ltd

    Improper function of certain messenger materials in the body that control body weight and hunger in people

    phase 3 small molecule active

    1 trial

  6. Solution for injection in pre-filled syringe without Ustekinumab 90, Solution for injection without Ustekinumab 45, STELARA 45 mg solution for injection, STELARA 90 mg solution for injection in pre-filled syringe, JNJ-77242113, Film-Coated Tablet without JNJ-77242113

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  7. Sonelokimab, Placebo is a sterile solution in a single use prefilled syringe (PFS) intended for subcutaneous administration

    MoonLake Immunotherapeutics

    hidradenitis suppurativa (HS)

    phase 3 small molecule active

    1 trial

  8. Sonelokimab, Placebo is a sterile solution in a single use prefilled syringe (PFS) intended for subcutaneous administration

    MoonLake Immunotherapeutics

    hidradenitis suppurativa (HS)

    phase 3 small molecule active

    1 trial

  9. Sonelokimab, Placebo is a sterile solution in a single use prefilled syringe (pfs) intended for subcutaneous administration

    MoonLake Immunotherapeutics

    Psoriatic arthritis

    phase 3 small molecule active

    1 trial

  10. Spesolimab - solution for infusion

    Boehringer Ingelheim

    Netherton Syndrome

    phase 3 small molecule terminated

    1 trial

  11. Spesolimab i.v.

    Boehringer Ingelheim

    Hidradenitis Suppurativa

    phase 3 small molecule completed

    1 trial

  12. Spesolimab, Placebo matching to Spesolimab

    Boehringer Ingelheim

    Hidradenitis Suppurativa (HS)

    phase 3 small molecule active

    1 trial

  13. Standard Brief Intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Usage

    phase 3 other completed

    1 trial

  14. Start antiplatelet monotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Intracerebral Hemorrhage

    phase 3 small molecule completed

    1 trial

  15. Statins

    Arrowhead Pharmaceuticals Ireland Limited

    Intracerebral Hemorrhage

    phase 3 small molecule active

    1 trial

  16. Sugammadex 100 mg/ml solution for injection, Rocuronium bromide 10 mg/ml solution for injection/infusion

    Istituto Gentili S.r.l.

    patients scheduled to undergo elective surgical procedures with general anesthesia

    phase 3 small molecule active

    1 trial

  17. Supportive care+Prednisone

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Minimal Change Disease

    phase 3 small molecule active

    1 trial

  18. Suprefact Depot 9,45 mg implantat, Pamorelin 11,25 mg, poeder en oplosmiddel voor suspensie voor injectie, met verlengde afgifte., Pamorelin 22,5 mg, poeder en oplosmiddel voor suspensie voor injectie, met verlengde afgifte., Pamorelin 3,75 mg, poeder en oplosmiddel voor suspensie voor injectie, met verlengde afgifte., Eligard 45 mg poeder en oplosmiddel voor oplossing voor injectie, LEUPRORELIN ACETATE, CAMCEVI 42 mg prolonged-release suspension for injection, Gonapeptyl Depot 3,75 mg poeder en oplosmiddel

    Disc Medicine

    low-volume metastatic castration-sensitive prostate cancer

    phase 3 small molecule active

    1 trial

  19. Suptavumab 30 mg/kg

    Regeneron UK Limited

    Respiratory Syncytial Virus Infections

    phase 3 small molecule completed

    1 trial

  20. Surgery and HIPEC with Lobaplatin

    Universal Integrated

    Colorectal Neoplasms

    phase 3 other active

    1 trial

  21. Surgery with an external ring fixator

    United Therapeutics Europe Ltd

    Severe Open Fractures of the Tibia (Shin) Bone

    phase 3 other completed

    1 trial

  22. Suspension of autologous mononuclear cells separated from bone marrow aspirate

    The George Institute

    diabetic foot syndrome, lower limb ischemia

    phase 3 small molecule active

    1 trial

  23. Synthetic Conjugated estrogens, B

    Teva Pharma GmbH

    Menopause

    phase 3 small molecule completed

    1 trial

  24. TACROLIMUS, ALPN-303 solution for injection in pre-filled syringe, TACROLIMUS, TACROLIMUS, ALPN-303 solution for injection, Test IMP without active substance, ALPN-303 Solution for Injection in Pre-filled Pen

    Vertex Pharmaceuticals (Australia) Pty.

    Primary Membranous Nephropathy

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources